Safeguard efficacy from day one.

Given that head lice resistance has rendered most OTC treatments ineffective1, current approaches to requesting therapy may be equally inadequate.

Why prior authorization matters

Subjecting patients to repeat use of ineffective agents and greater cost.2

Unnecessary exposure to pesticides from multiple use of OTCs or other known toxic agents.2

Ongoing stigma associated with head lice and the serious negative impact on mental health.2

References:

  1. Gellatly KJ, Krim S,Palenchar DJ, et al. Expansion of the knockdown resistance frequency map for human head lice (phthiraptera: pediculidae) in the United States using quantitative sequencing. Journal of Medical Entomology, 2016:1-7.
  2. DP West., Head Lice Treatment Costs and the Impact on Managed Care, Amer J of Managed Care, September 1, 2004]

NAT-RRW10-000

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.